Skip to main content
United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
284.73
-0.46 (-0.16%)
Apr 17, 2025, 4:00 PM EDT - Market closed

United Therapeutics Revenue by Segment
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Tyvaso
1.62B 1.56B 1.45B 1.37B 1.23B 1.13B 1.06B 939.40M
Tyvaso Growth
31.34% 38.18% 36.87% 45.60% 41.32% 41.17% 50.25% 43.09%
Remodulin
538.10M 518.70M 521.50M 501.40M 494.80M 502.20M 485.10M 489.90M
Remodulin Growth
8.75% 3.29% 7.50% 2.35% -1.08% 1.25% -4.39% -4.91%
Orenitram
434.30M 410.60M 389.40M 377.40M 359.40M 351.10M 346.60M 330.50M
Orenitram Growth
20.84% 16.95% 12.35% 14.19% 10.55% 9.17% 8.55% 4.42%
Unituxin
238.70M 225.40M 215.60M 208.20M 198.90M 181.40M 176.20M 176.40M
Unituxin Growth
20.01% 24.26% 22.36% 18.03% 8.75% -7.54% -14.22% -17.57%
Adcirca
23.80M 25.90M 26.20M 28.00M 28.90M 32.50M 35.90M 38.80M
Adcirca Growth
-17.65% -20.31% -27.02% -27.84% -30.02% -16.67% -16.32% -30.84%
Other
17.20M 15.60M - 12.00M 8.30M 8.20M - 6.30M
Other Growth
107.23% 90.24% - 90.48% -39.86% - - -37.00%

Revenue by Geography
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
2.74B 2.62B 2.49B 2.37B 2.20B 2.08B 2.00B 1.87B
United States Growth
24.41% 25.96% 24.63% 26.68% 21.39% 19.78% 21.06% 15.70%
International
137.70M 136.30M 129.50M 124.30M 125.30M 124.30M 115.30M 107.30M
International Growth
9.90% 9.65% 12.32% 15.84% 2.54% 0.65% -17.82% -27.79%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.